New Delhi: The Union Health Ministry has notified landmark NDCT Rules Amendments in a major regulatory reform designed to simplify approval processes, cut timelines and promote ease of doing business in India’s pharmaceutical and clinical research ecosystem.
These changes are expected to accelerate drug development, reduce regulatory burden and further position India as a global hub for pharmaceutical R&D.
NDCT Rules Amendments: Government Focuses on Faster Approvals & Reduced Compliance
The notified amendments are part of a broader commitment by the Government of India to reduce bureaucratic delays and strengthen the drug development and clinical research landscape.
The changes align with the directions of Hon’ble Prime Minister Narendra Modi to build a trust-based regulatory framework while promoting innovation and industry growth.
Key Details of NDCT Rules Amendments
The core focus of NDCT Rules amendments is to make regulatory procedures more transparent, predictable and easier for stakeholders — especially generic drug manufacturers, research organisations, and pharmaceutical innovators.
Ending Licence Requirement for Non-Commercial Manufacture
Under the earlier regulatory setup, companies needed to obtain a formal test licence from the Central Drugs Standard Control Organization (CDSCO) for manufacturing small quantities of drugs for research and testing. This process often took several weeks, delaying early stages of drug development.
What’s New?
- The requirement for a test licence for non-commercial manufacture has now been replaced with a “prior intimation” mechanism.
- Applicants can now submit an online intimation to CDSCO and proceed without waiting for a formal licence — except for a defined category of high-risk drugs such as cytotoxic drugs, narcotics and psychotropic substances, which still require a traditional licence.
This change is projected to save at least 90 days in the drug development cycle, significantly boosting speed and efficiency in early R&D stages.
Shorter Processing Time for Remaining Licenses
For the cases where a test licence is still required, the government has slashed the statutory processing period from 90 days to just 45 days.
This substantial reduction is expected to ease regulatory load for both the industry and CDSCO, which processes around 30,000-35,000 test licence applications annually.
Easier Bioavailability & Bioequivalence Studies
Bioavailability (BA) and Bioequivalence (BE) studies are critical steps in clinical development, especially for generic drugs. These studies show whether a new product behaves like an existing one in the body.
Under the revised rules:
- Prior permission is no longer needed for specified low-risk BA/BE studies.
- Instead, companies can start these studies based on a simple online intimation to CDSCO.
CDSCO handles around 4,000-4,500 BA/BE applications per year, and this change is expected to cut procedural delays significantly.
Digital Integration for Smooth Implementation
To ensure seamless compliance and transparency:
- Dedicated online modules will be launched on the National Single Window System (NSWS) and the SUGAM portal.
- These platforms will allow industry players to submit intimations and track approvals in a user-friendly and efficient manner.
What are the Benefits of NDCT Rules Amendments
Officials project that the reforms will:
- Substantially reduce regulatory burden on pharmaceutical companies.
- Facilitate quicker initiation of clinical studies, BA/BE tests, and drug analysis.
- Enable more efficient use of CDSCO’s manpower for oversight and safety monitoring.
By reducing compliance hurdles and timelines, this initiative is also expected to:
- Attract domestic and foreign investment in clinical research.
- Support quicker market entry for new and generic drugs.
- Strengthen India’s position as a preferred global destination for pharmaceutical R&D.
